Integrating AI with RWE to Accelerate Path to Market

1:00 PM - 1:45 PM (EST), Tuesday, February 7, 2023 ・ South Broadway Ballroom

The most recent FDA reauthorization legislation continues to support thoughtful expansion of real-world evidence (RWE) in new drug approval decision-making.  Leading companies are applying artificial intelligence algorithms to find the most relevant evidence amid mountains of real-world, clinical data to identify the patient subgroups and best biomarkers of indications to speed novel drug development, saving money and time versus traditional approaches.  A panel of experts will share their experiences and advice for applying AI to RWE to improve drug development program productivity. 

Moderator
photo
Founder and Managing Partner
Explorium Capital LLC
Speakers
photo
Founder and Managing Partner
Explorium Capital LLC
photo
VP, Fellow, Data Science
Valo Health
photo
Senior Vice President & General Manager, Real-World Evidence
Flatiron Health
photo
Senior Vice President of Customer Solutions and Quantitative Sciences
Verana Health
photo
Executive Committee Member
Alliance for Artificial Intelligence in Healthcare